Loading company
Exelixis, Inc.
EXEL · Nasdaq · ·
Next earnings: November 3, 2026
$58.66+0.5%Sep 29 close
- 1M
- +7.7%
- 6M
- +39.8%
- 1Y
- +42.0%
- 5Y
- +183.4%
EXEL · Nasdaq · ·
Next earnings: November 3, 2026
$58.66+0.5%Sep 29 close
Exelixis, Inc. is scheduled to report next on November 3, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending July 3, 2026, against the same quarter a year earlier.
| Measure | 3 months toJul 3, 2026 | 3 months toJul 4, 2025 | Change |
|---|---|---|---|
| Total Revenue | $628.7M | $568.3M | +10.63% |
| Profit | $212.1M | $184.8M | +14.72% |
| Profit per share | $0.82 | $0.65 | +26.15% |
| Free Cash Flow | $300.9M | $46.2M | +551.99% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Exelixis continues to execute across the key pillars of our business, positioning the company to deliver on our strategic objectives for 2026 and beyond,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules and biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our pipeline of franchise molecules, including our novel oral kinase inhibitor zanzalintinib, and to extend the impact of our flagship commercial product, CABOMETYX ® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com , follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Exelixis, Inc.’s Item 2.02 8-K filed August 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Exelixis, Inc. has no earnings call transcript available.